1. Home
  2. CAI vs CORT Comparison

CAI vs CORT Comparison

Compare CAI & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Caris Life Sciences Inc.

CAI

Caris Life Sciences Inc.

N/A

Current Price

$23.05

Market Cap

9.7B

Sector

Health Care

ML Signal

N/A

Logo Corcept Therapeutics Incorporated

CORT

Corcept Therapeutics Incorporated

N/A

Current Price

$72.91

Market Cap

9.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CAI
CORT
Founded
2008
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.7B
9.7B
IPO Year
2025
2001

Fundamental Metrics

Financial Performance
Metric
CAI
CORT
Price
$23.05
$72.91
Analyst Decision
Buy
Buy
Analyst Count
14
5
Target Price
$34.23
★ $142.60
AVG Volume (30 Days)
★ 3.8M
1.2M
Earning Date
11-04-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 69.79
N/A
EPS
0.05
★ 1.13
Revenue
★ $812,033,000.00
$761,407,000.00
Revenue This Year
$28.81
$52.09
Revenue Next Year
$19.11
$44.73
P/E Ratio
$477.70
★ $65.17
Revenue Growth
★ 96.97
12.79
52 Week Low
$14.19
$28.66
52 Week High
$36.50
$126.38

Technical Indicators

Market Signals
Indicator
CAI
CORT
Relative Strength Index (RSI) 31.26 26.07
Support Level $21.99 $30.24
Resistance Level $23.66 $122.93
Average True Range (ATR) 2.05 4.53
MACD -1.17 -0.39
Stochastic Oscillator 3.45 13.82

Price Performance

Historical Comparison
CAI
CORT

About CAI Caris Life Sciences Inc.

Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

Share on Social Networks: